INCLUSION CRITERIA: A YES RESPONSE IS REQUIRED FOR STUDY PARTICIPATION

1. Target ulcer is > 4 weeks and < 52 weeks old
2. Target ulcer is full-thickness but does not involve bone
3. Target ulcer is >0.25 cm² and <12 cm² (measured by length x width)
4. TcPO₂ and/or toe pressures are between 20 and 40 mm Hg
5. Age of patient > 18
6. Negative pregnancy test in women of child-bearing potential and commitment to use contraception for the duration of the study.

EXCLUSION CRITERIA: A NO RESPONSE IS REQUIRED FOR STUDY PARTICIPATION

7. Venous stasis ulcers on foot with target ulcer
8. Lower extremity arterial revascularization (either bypass surgery or angioplasty) less than 6 weeks prior to screening.
9. Charcot foot
10. More than 1+ pitting edema of the leg with target ulcer
11. Patient has exposed bone and/or osteomyelitis in leg with target ulcer
12. Patient is receiving radiation, chemotherapy, corticosteroids or immune system suppressants
13. History of congestive heart failure of any severity
14. Known thrombocytopenia
15. Known bleeding diathesis
16. Known intolerance to cilostazol or any of the ingredients of Pletal
17. Active peptic ulcer disease or GI bleeding
18. Known moderate or severe hepatic dysfunction
19. Current participation in another clinical trial (within 30 days)
20. Major life-threatening illness or prognosis of less than 1 year
21. Inability to give informed consent
22. Concurrent use of pentoxifylline
23. Concurrent use of ticlopidine
24. Concurrent use of hyperbaric oxygen
25. Concurrent use of arginine
26. Use of Pletal within 6 months of the trial
27. Informed consent signed

Signature of Investigator __________________________ Date: ___/___/____